Welcome to our dedicated page for CERO THERAPEUTICS HOLDINGS SEC filings (Ticker: CERO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CERO THERAPEUTICS HOLDINGS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CERO THERAPEUTICS HOLDINGS's regulatory disclosures and financial reporting.
CERO Therapeutics Holdings, Inc. has filed a prospectus supplement linked to an existing registration statement covering 729,596,950 shares of common stock, updating it with details of a new convertible financing. The common stock trades on OTCQB under “CERO,” with a last quoted bid of $0.0115 per share on July 16, 2026, and public warrants “CEROW” quoted at $0.0048 per warrant.
On July 14, 2026, the company entered into a second amended and restated convertible grid promissory note with SRX Global Inc. The Note allows tranche funding of up to $2,085,200, corresponding to a principal amount of up to $2,606,500 with a 25% original issue discount. Tranches of $750,000, $663,600, and $671,600 have been funded. The Note bears 10% annual interest, matures on May 28, 2027, and is convertible at the lender’s option at the lesser of $0.05 per share or 80% of the average of the five lowest intraday trading prices over the 20 days before a conversion request, subject to a 4.99% beneficial ownership limitation. The company is obligated to file a registration statement on Form S-1 or S-3 to register the resale of the conversion shares.
CERO Therapeutics Holdings, Inc. entered into a second amended and restated convertible promissory note with SRX Global Inc., allowing borrowings up to a maximum aggregate principal of $2,085,200. This amount has been funded in three tranches of $750,000, $663,600, and $671,600.
The note bears 10% annual interest, matures on May 28, 2027, and is convertible at the lender’s option into common stock at the lesser of $0.05 per share or 80% of the average of the five lowest intraday trading prices over the prior 20 days, subject to a 4.99% beneficial ownership limitation. The company plans to register the resale of conversion shares and relied on Securities Act private offering exemptions for this financing.
Cero Therapeutics Holdings, Inc. is having its common stock and warrants removed from listing and registration on the Nasdaq Stock Market LLC. Nasdaq certifies that it has complied with its own rules and the requirements of Section 12(b) and related SEC Rule 12d2-2 for striking the securities from listing, and the issuer is stated to have complied with the exchange’s rules and SEC requirements governing withdrawal of the securities.
CERO Therapeutics Holdings, Inc. files Prospectus Supplement No. 13 to its Form S-1 registering 729,596,950 shares of common stock. The supplement attaches a Form 8-K that discloses an amended and restated convertible promissory note providing up to $1,413,600 in aggregate loans, of which $750,000 was previously funded and an additional $663,600 funded on June 23, 2026. The Note bears interest at 10% per annum, matures on May 28, 2027, and is convertible into common stock at the lesser of $0.05 per share or 80% of a short-term average trading price, subject to a 4.99% beneficial ownership limitation. The supplement also states the company will file a registration statement covering resale of shares issuable upon conversion.
CERO Therapeutics Holdings, Inc. entered into an amended and restated convertible promissory note with SRX Health Solutions, Inc. on June 23, 2026. The note allows borrowing up to $1,413,600, of which $750,000 was previously funded and $663,600 was funded on June 23, 2026.
The note bears 10% annual interest, matures on May 28, 2027, and is convertible into common stock at the lesser of $0.05 per share or 80% of the average of the five lowest intraday trading prices during the 20 days before a conversion request, subject to a 4.99% beneficial ownership limitation. CERO agreed to file a registration statement on Form S-1 or S-3 to cover resale of shares issuable upon conversion. The issuance relied on private offering exemptions under Section 4(a)(2) and Rule 506(b) of the Securities Act.
CERO Therapeutics Holdings, Inc. is registering 729,596,950 shares of Common Stock via a Prospectus Supplement. The supplement attaches a Form 8-K that discloses the company issued a convertible promissory note on May 28, 2026.
The Note was purchased for $750,000 (principal face value $937,500), bears interest at 10% per annum, matures on May 28, 2027, and is convertible into Common Stock at a conversion price equal to the lesser of $0.05 or 80% of the average of the five lowest intraday trading prices during the twenty days before conversion, subject to a 4.99% beneficial ownership limitation. The Note requires the company to file a registration statement covering resale of shares issuable on conversion. The prospectus supplement also states recent bid prices: Common Stock $0.0191 and public warrants $0.0022.
CERo Therapeutics Holdings, Inc. entered into a financing agreement by issuing a convertible promissory note to SRX Health Solutions, Inc. for a purchase price of $750,000, with a principal face value of $937,500.
The Note bears interest at 10% per year and matures on May 28, 2027. The lender can convert principal and accrued interest into common stock at the lower of $0.05 per share or 80% of the average of the five lowest intraday trading prices during the 20 days before a conversion request, subject to a 4.99% beneficial ownership cap. CERo must file a Form S-1 or S-3 to register the resale of the conversion shares, and the transaction relies on private offering exemptions under Sections 4(a)(2) and 3(a)(9) of the Securities Act and Rule 506(b).
CERo Therapeutics Holdings, Inc. files a Prospectus Supplement registering 729,596,950 shares of Common Stock. The supplement incorporates the Company’s Form 10-Q for the quarter ended March 31, 2026 into the S-1 prospectus and updates disclosure, including liquidity and balance sheet items from the attached 10-Q.
The 10-Q shows cash, restricted cash, and cash equivalents of $857,489, a working capital deficit of approximately $9.8 million, a net loss of $5,885,914 for the three months ended March 31, 2026, and derivative liabilities measured at $2,396,722 as of March 31, 2026. The supplement should be read together with the Prospectus and replaces inconsistent prior Prospectus language.
CERo Therapeutics Holdings, Inc. reports Q1 2026 results showing continued operating losses and tight liquidity. The company posted a net loss of about $5.9 million for the quarter on operating expenses of roughly $4.8 million, primarily for research and development and general and administrative costs.
Cash, restricted cash and cash equivalents were only $857,489 as of March 31, 2026, while net cash used in operating activities was about $2.8 million. Total assets of roughly $2.2 million compare with total liabilities of about $11.5 million, resulting in stockholders’ deficit of approximately $9.3 million and a working capital deficit of about $9.8 million.
Management explicitly states that these conditions, together with an accumulated deficit of about $96.7 million and lack of revenue, raise substantial doubt about CERo’s ability to continue as a going concern within one year. To help fund operations, CERo raised about $2.0 million net during the quarter through equity line drawdowns and new 10% convertible notes, which also created significant derivative liabilities. The company remains an early-stage immunotherapy developer, with its lead T cell therapy CER-1236 in Phase 1/1b trials for acute myelogenous leukemia and prior FDA clearance of an IND for additional indications. CERo’s shares now trade on the OTCQB following a 2025 Nasdaq delisting.
CERO Therapeutics Holdings, Inc. filed Prospectus Supplement No. 10 to its Form S-1 registering 729,596,950 shares of Common Stock and attached a Form 8-K describing a convertible note financing.
The company issued a convertible promissory note with a purchase price of $400,000 (principal face value $500,000), permitting borrowings up to $1,000,000. The Note bears 10% interest, matures on April 27, 2027, and is convertible at the lesser of $0.05 per share or 80% of the average of the five lowest intraday prices during the 20 days prior to conversion, subject to a 4.99% beneficial ownership limitation. The company agreed to file a registration statement covering resale of shares issuable on conversion.